Compugen Ltd (CGEN) 7.03 $CGEN
Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy
PR Newswire - Tue Aug 30, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today disclosed that its LINKS computational platform, initially designed for the characterization and differentiation of existing novel drug target candidates, has been enhanced to include the in silico discovery of new immuno-oncology drug targets, with a specific focus on the discovery of myeloid targets within the tumor microenvironment (TME). LINKS now allows the Company to broaden its existing repertoire of immune checkpoint targets, which already includes a few myeloid targets, predicted by algorithms and methodologies previously developed by the Company. The myeloid targets, now being experimentally validated by the Company, have the potential to transform cancer treatment in patients that are non-responsive to treatments with current checkpoint inhibitors.
CGEN: 7.03 (+0.05)
How Compugen (CGEN) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:45AM CDT
Compugen (CGEN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
CGEN: 7.03 (+0.05)
Compugen Ltd. Reports 2nd Quarter 2016 Financial Results
PR Newswire - Tue Aug 02, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the second quarter ending June 30, 2016.
CGEN: 7.03 (+0.05)
Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program
PR Newswire - Wed Jun 22, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive therapeutic discovery company, today disclosed at the JMP Securities Life Science Conference in NY, COM701 as the lead monoclonal antibody therapeutic candidate for the Company's CGEN-15029 target program. This antibody candidate is now undergoing preclinical development activities in preparation for advancement to clinical trials, with an anticipated IND filing next year. CGEN-15029 is one of multiple novel immune checkpoint targets discovered by the Company through the use of its unique in silico predictive discovery infrastructure.
CGEN: 7.03 (+0.05)
Shares of CGEN Up 24.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:30PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 23.95% as of today's recent price of $6.65.
CGEN: 7.03 (+0.05)
Compugen Has Returned 29.5% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Jun 02, 12:51AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 29.54% as of today's recent price of $6.95.
CGEN: 7.03 (+0.05)
Compugen to Present at the Jefferies Global Healthcare Conference in New York
PR Newswire - Mon May 23, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Jefferies Global Healthcare Conference in New York, NY on Tuesday, June 7, 2016.
CGEN: 7.03 (+0.05)
Compugen Up 26.2% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Wed May 18, 12:57AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 26.19% as of today's recent price of $6.77.
CGEN: 7.03 (+0.05)
Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv
PR Newswire - Mon May 16, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Oppenheimer 17th Annual Israeli Conference in Tel Aviv, Israel on Sunday, May 22, 2016.
CGEN: 7.03 (+0.05)
Compugen Has Returned 31.1% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Tue May 10, 1:34PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.13% as of today's recent price of $7.04.
CGEN: 7.03 (+0.05)
Compugen reports 1Q loss
Automated Insights - Tue May 10, 6:14AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $8.6 million in its first quarter.
CGEN: 7.03 (+0.05)
Compugen Ltd. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the first quarter ended March 31, 2016.
CGEN: 7.03 (+0.05)
Compugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET
PR Newswire - Wed Apr 27, 6:15AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, May 10, 2016, to review the first quarter 2016 results. The quarterly results will be released on the Company's website (www.cgen.com) prior to the conference call.
CGEN: 7.03 (+0.05)
31.0% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Fri Apr 22, 12:44AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.03% as of today's recent price of $7.03.
CGEN: 7.03 (+0.05)
Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration With Bayer
PR Newswire - Mon Apr 18, 6:14AM CDT
Compugen Ltd. (NASDAQ: CGEN ), a leading predictive drug discovery company, announced today that it has achieved a first preclinical milestone for CGEN-15022 pursuant to its cancer immunotherapy collaboration with Bayer. The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022.
CGEN: 7.03 (+0.05)
Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.
PR Newswire - Wed Apr 06, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today that Elliott Sigal, M.D., Ph.D., former Executive Vice President and Director of Bristol-Myers Squibb, has joined Compugen Ltd. as a strategic advisor. The Company also announced that Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center at Johns Hopkins University of Medicine, and Chairman of Compugen's Scientific Advisory Board, has in addition joined the Board of Directors of Compugen USA, Inc., Compugen Ltd.'s wholly-owned antibody discovery and development subsidiary.
CGEN: 7.03 (+0.05), BMY: 57.39 (+0.15)
Compugen to Present at the Jefferies Immuno-Oncology Summit in Boston
PR Newswire - Mon Mar 28, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen, will present an overview of the Company's immuno-oncology programs and underlying predictive discovery capabilities at the Jefferies 2016 Immuno-Oncology Summit in Boston, on Thursday, April 7, 2016.
CGEN: 7.03 (+0.05)
Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy
PR Newswire - Tue Aug 30, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today disclosed that its LINKS computational platform, initially designed for the characterization and differentiation of existing novel drug target candidates, has been enhanced to include the in silico discovery of new immuno-oncology drug targets, with a specific focus on the discovery of myeloid targets within the tumor microenvironment (TME). LINKS now allows the Company to broaden its existing repertoire of immune checkpoint targets, which already includes a few myeloid targets, predicted by algorithms and methodologies previously developed by the Company. The myeloid targets, now being experimentally validated by the Company, have the potential to transform cancer treatment in patients that are non-responsive to treatments with current checkpoint inhibitors.
CGEN: 7.03 (+0.05)
How Compugen (CGEN) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:45AM CDT
Compugen (CGEN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
CGEN: 7.03 (+0.05)
Compugen Ltd. Reports 2nd Quarter 2016 Financial Results
PR Newswire - Tue Aug 02, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the second quarter ending June 30, 2016.
CGEN: 7.03 (+0.05)
Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program
PR Newswire - Wed Jun 22, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive therapeutic discovery company, today disclosed at the JMP Securities Life Science Conference in NY, COM701 as the lead monoclonal antibody therapeutic candidate for the Company's CGEN-15029 target program. This antibody candidate is now undergoing preclinical development activities in preparation for advancement to clinical trials, with an anticipated IND filing next year. CGEN-15029 is one of multiple novel immune checkpoint targets discovered by the Company through the use of its unique in silico predictive discovery infrastructure.
CGEN: 7.03 (+0.05)
Shares of CGEN Up 24.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:30PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 23.95% as of today's recent price of $6.65.
CGEN: 7.03 (+0.05)
Compugen Has Returned 29.5% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Jun 02, 12:51AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 29.54% as of today's recent price of $6.95.
CGEN: 7.03 (+0.05)
Compugen to Present at the Jefferies Global Healthcare Conference in New York
PR Newswire - Mon May 23, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Jefferies Global Healthcare Conference in New York, NY on Tuesday, June 7, 2016.
CGEN: 7.03 (+0.05)
Compugen Up 26.2% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Wed May 18, 12:57AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 26.19% as of today's recent price of $6.77.
CGEN: 7.03 (+0.05)
Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv
PR Newswire - Mon May 16, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Oppenheimer 17th Annual Israeli Conference in Tel Aviv, Israel on Sunday, May 22, 2016.
CGEN: 7.03 (+0.05)
Compugen Has Returned 31.1% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Tue May 10, 1:34PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.13% as of today's recent price of $7.04.
CGEN: 7.03 (+0.05)
Compugen reports 1Q loss
Automated Insights - Tue May 10, 6:14AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $8.6 million in its first quarter.
CGEN: 7.03 (+0.05)
Compugen Ltd. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the first quarter ended March 31, 2016.
CGEN: 7.03 (+0.05)
Compugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET
PR Newswire - Wed Apr 27, 6:15AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, May 10, 2016, to review the first quarter 2016 results. The quarterly results will be released on the Company's website (www.cgen.com) prior to the conference call.
CGEN: 7.03 (+0.05)
31.0% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Fri Apr 22, 12:44AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.03% as of today's recent price of $7.03.
CGEN: 7.03 (+0.05)
Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration With Bayer
PR Newswire - Mon Apr 18, 6:14AM CDT
Compugen Ltd. (NASDAQ: CGEN ), a leading predictive drug discovery company, announced today that it has achieved a first preclinical milestone for CGEN-15022 pursuant to its cancer immunotherapy collaboration with Bayer. The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022.
CGEN: 7.03 (+0.05)
Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.
PR Newswire - Wed Apr 06, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today that Elliott Sigal, M.D., Ph.D., former Executive Vice President and Director of Bristol-Myers Squibb, has joined Compugen Ltd. as a strategic advisor. The Company also announced that Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center at Johns Hopkins University of Medicine, and Chairman of Compugen's Scientific Advisory Board, has in addition joined the Board of Directors of Compugen USA, Inc., Compugen Ltd.'s wholly-owned antibody discovery and development subsidiary.
CGEN: 7.03 (+0.05), BMY: 57.39 (+0.15)
Compugen to Present at the Jefferies Immuno-Oncology Summit in Boston
PR Newswire - Mon Mar 28, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen, will present an overview of the Company's immuno-oncology programs and underlying predictive discovery capabilities at the Jefferies 2016 Immuno-Oncology Summit in Boston, on Thursday, April 7, 2016.
CGEN: 7.03 (+0.05)
